Search PubMed⌕ Search

Biomedical subjects

H Yabe

Publications and source records attributed to H Yabe.

At least 109 records · Page 6Linked to original sources
PubMed1989

Systemic lupus erythematosus in a patient with refractory anemia.

A 69-year-old man was diagnosed as having refractory anemia (RA), accompanied by pancytopenia of two years' duration, myelodysplasia in all three cell lines, abnormal karyotype of 46, XY, 20q--in bone marrow cells, and positive antinuclear and DNA antibody tests. One year after his first visit, he developed arthritis and maculopapular erythematous rashes. The histologic features of the skin lesions were similar to those of in discoid lupus erythematosus. He was diagnosed as having systemic lupus erythematosus supervening refractory anemia.

Aged↗
PubMed1989

[Refractory anemia complicated by Behçet's disease--report of three cases].

Three cases of refractory anemia (RA) are presented. They developed a complete, an intestinal, and an incomplete type of Behçet's disease after 13 years, 6 months, and 4 years of illness, respectively. They showed normal or only slightly reduced neutrophil counts in spite of anemia and thrombocytopenia. Although the precise etiology of Behçet's disease is still obscure, it is suggested that immunological reactions against Streptococcus viridans in chronic infection, and auto-oxidative damage induced by oxygen intermediates derived from stimulated neutrophils may play an important role in causing endothelial injury in the disease. Therefore, it is possible to speculate in our cases that the known susceptibility to bacterial infections in myelodysplastic syndromes, and the absence of neutropenia may have been responsible for the association of RA with Behçet's disease. It is also suggested that neutrophils are necessary for endothelial cell damage.

Adult↗
PubMed1989

[Empirical antibiotic therapy in febrile neutropenic patients with acute leukemia].

One hundred and ninety-five episodes of fever during the neutropenic phase of chemotherapy in 49 patients with acute leukemia from 1984 to 1987 were analyzed with the following results: 1) Febrile episodes occurred in 80 percent of the neutropenic (less than 500/microliters) phase lasting more than 7 days after chemotherapy. 2) Febrile episodes consisted of 44 (22%) of established septicemia and 111 (57%) of suspected septicemia. 3) The pathogens causing septicemia were 8 GPC, 38 GNB (22 Pseudomonas species) and 6 fungi. Fungemia was confirmed on an average of 4.8 days after the onset of fever. The mortality of septic events was 10 out of 17 episodes (59%) when treated with antibiotics alone, while 8 out 27 (30%) with the combination of antibiotics plus antifungal drugs. 4) The mortality of suspected sepsis was only 2 out of 111 episodes. Eighty-three (75%) of these 111 episodes responded to antibiotics alone, while 26 (23%) cases needed antibiotics plus antifungal drugs. Our results suggest that in febrile neutropenic patient empiric broad-spectrum antibiotic therapy should be initiated which is especially effective for Pseudomonas species, but if fever persists despite more than 4 or 5 days of antibiotic therapy, additional antifungal therapy should be considered.

Acute Disease↗
PubMed1989

The origin of the osteoclast.

The origin of the osteoclast remains controversial even though investigations using light microscopy, tissue culture, electron microscopy, microcinematography, autoradiography, parabiosis, quail chick nuclear markers, giant lysosomal markers in beige mice, Y chromosomes, bone marrow cell culture, and monoclonal antibodies have been performed since its discovery. Concepts of the origin of the osteoclast have been changing. The classic concept was that the osteoclast originated from connective tissue cells. Others hypothesized that it originated from mature hematopoietic cells, particularly from monocyte or macrophage cells. A recent concept proposed an origin from hematopoietic stem cells. The hematopoietic stem cell was believed to differentiate into two cell lineages: one of monocytes and the other of preosteoclasts. The authors' concept, based on experimental observations as well as alternate interpretations stemming from experimental reports of other researchers, proposes an origin from local, nonhematopoietic, possibly perivascular mesenchymal cells. However, the relationship of the hematopoietic stem cells to perivascular mesenchymal cells in the periosteum at an early stage of enchondral ossification is still not well known. Therefore, the origin of the osteoclast also remains uncertain.

Animals↗
PubMed1988

Osteoclasts in human osteopetrosis contain viral-nucleocapsid-like nuclear inclusions.

We report the discovery of nuclear inclusions in the osteoclasts of three unrelated patients with benign osteopetrosis that resemble the osteoclast inclusions characteristic of Paget's disease of bone. These inclusions are morphologically and dimensionally identical to the nucleocapsids of a virus of the Paramyxoviridae family. Supporting a possible viral association with benign osteopetrosis in the observation of the presence of antigens of respiratory syncytial virus, measles virus, and/or mumps virus in the cells of all five patients whose paraffin-embedded bone specimens were tested. These included two patients whose osteoclasts contained nuclear inclusions. No patients with the malignant form of the disease have been studied. There is as yet no proof that a virus is causally related to human osteopetrosis even though a virus can produce an avian form of the disease.

Adult↗
PubMed1988

Use of Broviac/Hickman catheter for long-term venous access in pediatric cancer patients.

Forty-two indwelling central venous catheters were inserted in 29 pediatric patients with malignant solid tumors. Indications included pre- and postoperative parenteral nutrition, intensive chemo-radiotherapy and bone marrow transplantation. Fifteen of the central venous catheters (15 patients) were Broviac/Hickman and remaining 27 catheters (14 patients) were traditional Silastic. Accidental displacements occurred in seven of the 27 Silastics (26%), whereas no Broviac catheter was inadvertently pulled out. Overall complication rates, including infection, accidental removal, and occlusion of the catheter, were 9.6 per 1,000 Silastic use days and 0.35 per 1,000 Broviac use days. No deaths were related to catheter complications. For long-term angioaccess in pediatric cancer patient the Broviac catheter was demonstrated to have a lower complication rate than the traditional Silastic catheter.

Adolescent↗
PubMed1988

A trial of alloreactive T-cell depletion using biotinylated galactose oxidase for the prevention of acute graft-versus-host diseases.

Galactose oxidase was labelled onto the surface of mitomycin-C treated splenic lymphocytes from BALB/C mice (H-2d, Mlsb). Mouse splenic lymphocytes from DBA/2 (H-2d, Mlsa) mixed with the galactose oxidase labelled BALB/C lymphocytes allowed DBA/2 cells which recognized the Mlsb on the BALB/C cells to make direct contact with the galactose oxidase labelled BALB/C cells. By adding galactose, sodium iodide and catalase to the mixture, the contacting stimulator cells will generate hydrogen peroxide in the vicinity of the contacting responder cells and the iodine ions will exert a toxic effect on the responder cells while non-specific cytotoxicity was prevented by catalase. When fresh mitomycin-C treated BALB/C lymphocytes were added to the cell mixture, the mixed lymphocyte response against BALB/C cells by the treated DBA/2 lymphocytes was abolished. On the other hand, when fresh mitomycin-C treated lymphocytes from C57BL/6 mice (H-2b, Mlsb) were mixed with the treated DBA/2 cells, the mixed lymphocyte response against C57BL/6 cells by the treated DBA/2 lymphocytes was partially retained. Therefore, although some non-specific cytotoxicity was present, a method to deplete specific T-lymphocytes that recognize major histocompatibility antigen from a mixed cell population while maintaining immune responsiveness towards other antigens was developed. This method may have a beneficial effect on the control of post-transplant immunity and may be used as a prophylaxis of graft-versus-host disease.

Animals↗